InvestorsObserver
×
News Home

Aerovate Therapeutics Inc (AVTE) has gained 4.60% in a Week, Should You Hold?

Wednesday, March 27, 2024 10:42 AM | InvestorsObserver Analysts

Mentioned in this article

Aerovate Therapeutics Inc (AVTE) has gained 4.60% in a Week, Should You Hold?

The 67 rating InvestorsObserver gives to Aerovate Therapeutics Inc (AVTE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 80 percent of stocks in the Biotechnology industry, AVTE’s 67 overall rating means the stock scores better than 67 percent of all stocks.

Overall Score - 67
AVTE has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on AVTE!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Aerovate Therapeutics Inc Stock Today?

Aerovate Therapeutics Inc (AVTE) stock is trading at $27.08 as of 10:34 AM on Wednesday, Mar 27, an increase of $1.43, or 5.58% from the previous closing price of $25.65. The stock has traded between $25.62 and $27.40 so far today. Volume today is low. So far 27,789 shares have traded compared to average volume of 119,192 shares. Click Here to get the full Stock Report for Aerovate Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App